Publications

Publications of the Lab of Cancer Biology.

Publications

2025

  1. CCN3/IMP3/HIF1alpha positive feedback loop enhances malignant progression of triple-negative breast cancer
    Son, S., Jo, S., Lim, H., Kang, M. G., Lee, J. H., Lee, C. J., Lee, K. M., Shin, I.. Cell Signal. 2025.
  2. CD8+ T cells in the tumor microenvironment modulate response to endocrine therapy in breast cancer
    Napolitano, F., Wang, Y., Sudhan, D. R., Gonzalez-Ericsson, P. I., Formisano, L., Unni, N., Shakeel, S., Zhu, J. Z., Ahuja, K., Guo, L., Chica-Parrado, M. R., Matsunaga, Y., Luna, P., Lin, C. A., Uemoto, Y., Lee, K. M., Ma, H., Evans, N. J., Servetto, A., Mendiratta, S., Barnes, S. D., Bianco, R., Fang, Y. V., Xu, L., Lee, J., Wang, T., Balko, J. M., Mills, G. B., Labrie, M., Hanker, A. B., Arteaga, C. L.. J Clin Invest. 2025.
  3. Nidogen-1 suppresses cell proliferation, migration, and glycolysis via integrin beta1-mediated HIF-1alpha downregulation in triple-negative breast cancer
    Lee, J. H., Son, S., Ko, Y., Lim, H., Lee, M., Kang, M. G., Kim, H., Lee, K. M., Shin, I.. Sci Rep. 2025.

2024

  1. Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor subtype of triple negative breast cancer
    Chica-Parrado, M. R., Kim, G. M., Uemoto, Y., Napolitano, F., Lin, C. C., Ye, D., Bikorimana, E., Fang, Y., Lee, K. M., Mendiratta, S., Hanker, A. B., Arteaga, C. L.. Cancer Lett. 2024.
  2. PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer
    Lin, C. C., Chang, T. C., Wang, Y., Guo, L., Gao, Y., Bikorimana, E., Lemoff, A., Fang, Y. V., Zhang, H., Zhang, Y., Ye, D., Soria-Bretones, I., Servetto, A., Lee, K. M., Luo, X., Otto, J. J., Akamatsu, H., Napolitano, F., Mani, R., Cescon, D. W., Xu, L., Xie, Y., Mendell, J. T., Hanker, A. B., Arteaga, C. L.. Nat Commun. 2024.

2023

  1. Special Issue: Resistance to Targeted Therapies in Human Cancer
    Lee, T. W., Choi, H. J., Lee, K. M., Lee, J. Y.. Biomedicines. 2023.
  2. CCN3/NOV promotes metastasis and tumor progression via GPNMB-induced EGFR activation in triple-negative breast cancer
    Son, S., Kim, H., Lim, H., Lee, J. H., Lee, K. M., Shin, I.. Cell Death Dis. 2023.

2022

  1. Brain type of creatine kinase induces doxorubicin resistance via TGF-beta signaling in MDA-MB-231 breast cancer cells
    Son, S., Yoo, S. A., Nam, K., Oh, S., Lee, K. M., Yi, J. Y., Shin, I.. Anim Cells Syst (Seoul). 2022.
  2. Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer
    Lee, K. M., Lin, C. C., Servetto, A., Bae, J., Kandagatla, V., Ye, D., Kim, G., Sudhan, D. R., Mendiratta, S., Gonzalez Ericsson, P. I., Balko, J. M., Lee, J., Barnes, S., Malladi, V. S., Tabrizi, S., Reddy, S. M., Yum, S., Chang, C. W., Hutchinson, K. E., Yost, S. E., Yuan, Y., Chen, Z. J., Fu, Y. X., Hanker, A. B., Arteaga, C. L.. Cancer Immunol Res. 2022.
  4. ECM1 is associated with endocrine resistance in ER+ breast cancers
    Lee, T. W., Lee, K. M.. Anim Cells Syst (Seoul). 2022.

2021

  1. Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer
    Servetto, A., Kollipara, R., Formisano, L., Lin, C. C., Lee, K. M., Sudhan, D. R., Gonzalez-Ericsson, P. I., Chatterjee, S., Guerrero-Zotano, A., Mendiratta, S., Akamatsu, H., James, N., Bianco, R., Hanker, A. B., Kittler, R., Arteaga, C. L.. Clin Cancer Res. 2021.
  2. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity
    Hanker, A. B., Brown, B. P., Meiler, J., Marin, A., Jayanthan, H. S., Ye, D., Lin, C. C., Akamatsu, H., Lee, K. M., Chatterjee, S., Sudhan, D. R., Servetto, A., Brewer, M. R., Koch, J. P., Sheehan, J. H., He, J., Lalani, A. S., Arteaga, C. L.. Cancer Cell. 2021.

2020

  1. Proline rich 11 overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer
    Lee, K. M., Guerrero-Zotano, A. L., Servetto, A., Sudhan, D. R., Lin, C. C., Formisano, L., Jansen, V. M., Gonzalez-Ericsson, P., Sanders, M. E., Stricker, T. P., Raj, G., Dean, K. M., Fiolka, R., Cantley, L. C., Hanker, A. B., Arteaga, C. L.. Nat Commun. 2020.
  2. A versatile oblique plane microscope for large-scale and high-resolution imaging of subcellular dynamics
    Sapoznik, E., Chang, B. J., Huh, J., Ju, R. J., Azarova, E. V., Pohlkamp, T., Welf, E. S., Broadbent, D., Carisey, A. F., Stehbens, S. J., Lee, K. M., Marin, A., Hanker, A. B., Schmidt, J. C., Arteaga, C. L., Yang, B., Kobayashi, Y., Tata, P. R., Kruithoff, R., Doubrovinski, K., Shepherd, D. P., Millett-Sikking, A., York, A. G., Dean, K. M., Fiolka, R. P.. eLife. 2020.
  3. Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers
    Sudhan, D. R., Guerrero-Zotano, A., Won, H., Ericsson, P. G., Servetto, A., Huerta-Rosario, M., Ye, D., Lee, K. M., Formisano, L., Guo, Y., Liu, Q., Kinch, L. N., Brewer, M. R., Dugger, T., Koch, J., Wick, M. J., Cutler, R. E., Lalani, A. S., Bryce, R., Auerbach, A., Hanker, A. B., Arteaga, C. L.. Cancer Cell. 2020.

2019

  1. Elacestrant exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors
    Patel, H. K., Tao, N., Lee, K. M., Huerta, M., Arlt, H., Mullarkey, T., Troy, S., Arteaga, C. L., Bihani, T.. Breast Cancer Res. 2019.
  2. Discovery of Potent Myeloid Cell Leukemia-1 Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer
    Lee, T., Christov, P. P., Shaw, S., Tarr, J. C., Zhao, B., Veerasamy, N., Jeon, K. O., Mills, J. J., Bian, Z., Sensintaffar, J. L., Arnold, A. L., Fogarty, S. A., Perry, E., Ramsey, H. E., Cook, R. S., Hollingshead, M., Davis Millin, M., Lee, K. M., Koss, B., Budhraja, A., Opferman, J. T., Kim, K., Arteaga, C. L., Moore, W. J., Olejniczak, E. T., Savona, M. R., Fesik, S. W.. J Med Chem. 2019.
  3. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
    Formisano, L., Lu, Y., Servetto, A., Hanker, A. B., Jansen, V. M., Bauer, J. A., Sudhan, D. R., Guerrero-Zotano, A. L., Croessmann, S., Guo, Y., Ericsson, P. G., Lee, K. M., Nixon, M. J., Schwarz, L. J., Sanders, M. E., Dugger, T. C., Cruz, M. R., Behdad, A., Cristofanilli, M., Bardia, A., O'Shaughnessy, J., Nagy, R. J., Lanman, R. B., Solovieff, N., He, W., Miller, M., Su, F., Shyr, Y., Mayer, I. A., Balko, J. M., Arteaga, C. L.. Nat Commun. 2019.

2018

  1. ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
    Guerrero-Zotano, A. L., Stricker, T. P., Formisano, L., Hutchinson, K. E., Stover, D. G., Lee, K. M., Schwarz, L. J., Giltnane, J. M., Estrada, M. V., Jansen, V. M., Servetto, A., Gavila, J., Perez-Fidalgo, J. A., Lluch, A., Llombart-Cussac, A., Bayar, M. A., Michiels, S., Andre, F., Arnedos, M., Guillem, V., Ruiz-Simon, A., Arteaga, C. L.. Clin Cancer Res. 2018.
  2. PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase, Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3Kalpha Inhibitors
    Croessmann, S., Sheehan, J. H., Lee, K. M., Sliwoski, G., He, J., Nagy, R., Riddle, D., Mayer, I. A., Balko, J. M., Lanman, R., Miller, V. A., Cantley, L. C., Meiler, J., Arteaga, C. L.. Clin Cancer Res. 2018.

2017

  1. MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation
    Lee, K. M., Giltnane, J. M., Balko, J. M., Schwarz, L. J., Guerrero-Zotano, A. L., Hutchinson, K. E., Nixon, M. J., Estrada, M. V., Sanchez, V., Sanders, M. E., Lee, T., Gomez, H., Lluch, A., Perez-Fidalgo, J. A., Wolf, M. M., Andrejeva, G., Rathmell, J. C., Fesik, S. W., Arteaga, C. L.. Cell Metab. 2017.
  2. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer
    Jansen, V. M., Bhola, N. E., Bauer, J. A., Formisano, L., Lee, K. M., Hutchinson, K. E., Witkiewicz, A. K., Moore, P. D., Estrada, M. V., Sanchez, V., Ericsson, P. G., Sanders, M. E., Pohlmann, P. R., Pishvaian, M. J., Riddle, D. A., Dugger, T. C., Wei, W., Knudsen, E. S., Arteaga, C. L.. Cancer Res. 2017.

2015

  2. EGFR negates the proliferative effect of oncogenic HER2 in MDA-MB-231 cells
    Oh, S., Ju, J. H., Yang, W., Lee, K. M., Nam, K., Shin, I.. Arch Biochem Biophys. 2015.
  3. Cytokeratin19 induced by HER2/ERK binds and stabilizes HER2 on cell membranes
    Ju, J. H., Oh, S., Lee, K. M., Yang, W., Nam, K. S., Moon, H. G., Noh, D. Y., Kim, C. G., Park, G., Park, J. B., Lee, T., Arteaga, C. L., Shin, I.. Cell Death Differ. 2015.
  4. ECM1 regulates tumor metastasis and CSC-like property through stabilization of beta-catenin
    Lee, K. M., Nam, K., Oh, S., Lim, J., Kim, R. K., Shim, D., Choi, J. H., Lee, S. J., Yu, J. H., Lee, J. W., Ahn, S. H., Shin, I.. Oncogene. 2015.
  5. ECM1 promotes the Warburg effect through EGF-mediated activation of PKM2
    Lee, K. M., Nam, K., Oh, S., Lim, J., Lee, T., Shin, I.. Cell Signal. 2015.

2014

  1. Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor signaling
    Lee, K. M., Nam, K., Oh, S., Lim, J., Kim, Y. P., Lee, J. W., Yu, J. H., Ahn, S. H., Kim, S. B., Noh, D. Y., Lee, T., Shin, I.. Breast Cancer Res. 2014.
  3. S100A4 negatively regulates beta-catenin by inducing the Egr-1-PTEN-Akt-GSK3beta degradation pathway
    Yang, W., Nam, K., Ju, J. H., Lee, K. M., Oh, S., Shin, I.. Cell Signal. 2014.

2013

  1. Regulation of cell proliferation and migration by keratin19-induced nuclear import of early growth response-1 in breast cancer cells
    Ju, J. H., Yang, W., Lee, K. M., Oh, S., Nam, K., Shim, S., Shin, S. Y., Gye, M. C., Chu, I. S., Shin, I.. Clin Cancer Res. 2013.
  2. HER2 stabilizes survivin while concomitantly down-regulating survivin gene transcription by suppressing Notch cleavage
    Ju, J. H., Yang, W., Oh, S., Nam, K., Lee, K. M., Noh, D. Y., Shin, I.. Biochem J. 2013.
  3. Protein kinase B/Akt1 inhibits autophagy by down-regulating UVRAG expression
    Yang, W., Ju, J. H., Lee, K. M., Nam, K., Oh, S., Shin, I.. Exp Cell Res. 2013.

2012

2011

  1. CD24 enhances DNA damage-induced apoptosis by modulating NF-kappaB signaling in CD44-expressing breast cancer cells
    Ju, J. H., Jang, K., Lee, K. M., Kim, M., Kim, J., Yi, J. Y., Noh, D. Y., Shin, I.. Carcinogenesis. 2011.
  2. Induction of apoptotic cell death by Pharbitis nil extract in HER2-overexpressing MCF-7 cells
    Ju, J. H., Jeon, M. J., Yang, W., Lee, K. M., Seo, H. S., Shin, I.. J Ethnopharmacol. 2011.
  3. Akt isoform-specific inhibition of MDA-MB-231 cell proliferation
    Yang, W., Ju, J. H., Lee, K. M., Shin, I.. Cell Signal. 2011.

2010

  1. Effects of endocrine disruptors on Bombina orientalis P450 aromatase activity
    Lee, K. M., Yang, W., Rhee, J. S., Hwang, D. S., Park, C. J., Gye, M. C., Lee, J. S., Shin, I.. Zoolog Sci. 2010.